217 related articles for article (PubMed ID: 31641029)
1. Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia.
Bruno C; Pearson SA; Daniels B; Buckley NA; Schaffer A; Zoega H
BMJ Qual Saf; 2020 May; 29(5):365-373. PubMed ID: 31641029
[TBL] [Abstract][Full Text] [Related]
2. Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia.
Wu J; Dickinson S; Elgebaly Z; Blogg S; Heaney A; Soo Y; Daniels B; Weekes L
BMC Fam Pract; 2020 May; 21(1):85. PubMed ID: 32386520
[TBL] [Abstract][Full Text] [Related]
3. The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis.
Daniels B; Schaffer A; Buckley NA; Bruno C; Jun M; Pearson SA; Zoega H
Pharmacoepidemiol Drug Saf; 2022 Mar; 31(3):370-378. PubMed ID: 34894368
[TBL] [Abstract][Full Text] [Related]
4. Use of proton pump inhibitors among older Australians: national quality improvement programmes have led to sustained practice change.
Pratt NL; Kalisch Ellett LM; Sluggett JK; Gadzhanova SV; Ramsay EN; Kerr M; LeBlanc VT; Barratt JD; Roughead EE
Int J Qual Health Care; 2017 Feb; 29(1):75-82. PubMed ID: 27920248
[TBL] [Abstract][Full Text] [Related]
5. The crux of the matter: Did the ABC's Catalyst program change statin use in Australia?
Schaffer AL; Buckley NA; Dobbins TA; Banks E; Pearson SA
Med J Aust; 2015 Jun; 202(11):591-5. PubMed ID: 26068693
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Prescribing Patterns Before and After Implementation of a National Policy to Reduce Inappropriate Alprazolam Prescribing in Australia.
Schaffer AL; Buckley NA; Cairns R; Pearson S
JAMA Netw Open; 2019 Sep; 2(9):e1911590. PubMed ID: 31532519
[TBL] [Abstract][Full Text] [Related]
7. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
[TBL] [Abstract][Full Text] [Related]
8. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
Linton A; Bacon T; Peterson M
J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
[TBL] [Abstract][Full Text] [Related]
9. The impact of permissive and restrictive pharmaceutical policies on quetiapine dispensing: Evaluating a policy pendulum using interrupted time series analysis.
Brett J; Schaffer A; Dobbins T; Buckley NA; Pearson SA
Pharmacoepidemiol Drug Saf; 2018 Apr; 27(4):439-446. PubMed ID: 29493050
[TBL] [Abstract][Full Text] [Related]
10. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.
McGinn D; Godman B; Lonsdale J; Way R; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):73-85. PubMed ID: 20121565
[TBL] [Abstract][Full Text] [Related]
11. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study.
Lassalle M; Le Tri T; Bardou M; Biour M; Kirchgesner J; Rouby F; Dumarcet N; Zureik M; Dray-Spira R
Eur J Clin Pharmacol; 2020 Mar; 76(3):449-457. PubMed ID: 31838548
[TBL] [Abstract][Full Text] [Related]
12. Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016.
Daniels B; Pearson SA; Buckley NA; Bruno C; Zoega H
Therap Adv Gastroenterol; 2020; 13():1756284820913743. PubMed ID: 32218806
[TBL] [Abstract][Full Text] [Related]
13. The impact of tightened prescribing restrictions for PBS-subsidised opioid medicines and the introduction of half-pack sizes, Australia, 2020-21: an interrupted time series analysis.
Koch FC; Olivier J; Brett J; Buckley NA; Gisev N; Pearson S; Daniels B
Med J Aust; 2024 Apr; 220(6):315-322. PubMed ID: 38522006
[TBL] [Abstract][Full Text] [Related]
14. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital.
Luo H; Fan Q; Xiao S; Chen K
BMC Health Serv Res; 2018 Jul; 18(1):537. PubMed ID: 29996830
[TBL] [Abstract][Full Text] [Related]
15. Strategies for reducing the prescribing of proton pump inhibitors (PPIs): patient self-regulation of treatment may be an under-exploited resource.
Pollock K; Grime J
Soc Sci Med; 2000 Dec; 51(12):1827-39. PubMed ID: 11128270
[TBL] [Abstract][Full Text] [Related]
16. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital.
Ramirez E; Lei SH; Borobia AM; Piñana E; Fudio S; Muñoz R; Campos A; Carcas AJ; Frias J
Curr Clin Pharmacol; 2010 Nov; 5(4):288-97. PubMed ID: 20925644
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of proton pump inhibitors anti-ulcer drugs use in the Araba district primary care area].
Martínez Gorostiaga J; Echevarría Orella E; Calvo Hernáez B
Rev Esp Salud Publica; 2018 Aug; 92():. PubMed ID: 30100604
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors: a study of GPs' prescribing.
Jones MI; Greenfield SM; Jowett S; Bradley CP; Seal R
Fam Pract; 2001 Jun; 18(3):333-8. PubMed ID: 11356744
[TBL] [Abstract][Full Text] [Related]
19. Trends in prescribing proton pump inhibitors in Taiwan: 1997 - 2000.
Chen TJ; Chou LF; Hwang SJ
Int J Clin Pharmacol Ther; 2003 May; 41(5):207-12. PubMed ID: 12776811
[TBL] [Abstract][Full Text] [Related]
20. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.
Fraeyman J; Van Hal G; Godman B; Beutels P
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):141-51. PubMed ID: 23402454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
